Transforming growth factor-β and ischemic brain injury

被引：84

作者：

Alain Buisson ^{[1
]}

Sylvain Lesne ^{[1
]}

Fabian Docagne ^{[1
]}

Carine Ali ^{[1
]}

Olivier Nicole ^{[1
]}

Eric T. MacKenzie ^{[1
]}

Denis Vivien ^{[1
]}

机构：

[1] Université de CAEN, UMR CNRS 6551, Centre CYCERON, Caen Cedex, bd H. Becquerel

[2] Universite de CAEN-CNRS UMR 6551, Centre CYCERON, IFR 47

来源：

Cellular and Molecular Neurobiology | 2003年 / 23卷 / 4-5期

关键词：

Cerebral ischemia; Molecular; TGF-β;

D O I：

10.1023/A:1025072013107

中图分类号：

学科分类号：

摘要：

1. Necrosis and apoptosis are the two fundamental hallmarks of neuronal death in stroke. Nevertheless, thrombolysis, by using the recombinant serine protease t-PA, remains until now the only approved treatment of stroke in man. 2. Over the last years, the cytokine termed Transforming Growth Factor-β1 (TGF-β1) has been found to be strongly up-regulated in the central nervous system following ischemia-induced brain damage. 3. Recent studies have shown a neuroprotective activity of TGF-β1 against ischemia-induced neuronal death. In vitro, TGF-β1 protects neurons against excitotoxicity by inhibiting the t-PA-potentiated NMDA-induced neuronal death through a mechanism involving the up-regulation of the type-1 plasminogen activator inhibitor (PAI-1) in astrocytes. 4. In addition, TGF-β1 has been recently characterized as an antiapoptotic factor in a model of staurosporine-induced neuronal death through a mechanism involving activation of the extracellular signal-regulated kinase 1/2 (Erk1/2) and a concomitant increase phosphorylation of the antiapoptotic protein Bad. 5. Altogether, these observations suggest that either TGF-β signaling or TGF-β1-modulated genes could be good targets for the development of new therapeutic strategies for stroke in man.

引用

页码：539 / 550

页数：11

共 53 条

[1] Ali C., Nicole O., Docagne F., Lesne S., MacKenzie E.T., Buisson A., Vivien D., Ischemia-induced interleukin-6 as a potential endogenous neuroprotective cytokine against NMDA receptor-mediated excitotoxicity in the brain, J. Cereb. Blood Flow Metab., 20, pp. 956-966, (2000)
[2] Artavanis-Tsakonas S., Rand M.D., Lake R., Notch signaling: Cell fate control and signal integration in development, Science, 284, pp. 770-776, (1999)
[3] Boldin M.P., Goncharov T.M., Goltsev Y.V., Wallach D., Involvement of MACH, a novel MORT1/FADD-interacting protease, in Fas/APO-1- and TNF receptor-induced cell death, Cell, 85, pp. 803-815, (1996)
[4] Buisson A., Nicole O., Docagne F., Sartelet H., MacKenzie E.T., Vivien D., Up-regulation of a serine protease inhibitor in astrocytes mediates the neuroprotective activity of transforming growth factor β1, FASEB J., 12, pp. 1683-1691, (1998)
[5] Cataldo A.M., Barnett J.L., Pieroni C., Nixon R.A., Increased neuronal endocytosis and protease delivery to early endosomes in sporadic Alzheimer's disease: Neuropathologic evidence for a mechanism of increased β-amyloidogenesis, J. Neurosci., 17, pp. 6142-6151, (1997)
[6] Choi D.W., Excitotoxic cell death, J. Neurobiol., 23, pp. 1261-1276, (1992)
[7] Docagne F., Nicole O., Marti H.H., MacKenzie E.T., Buisson A., Vivien D., Transforming growth factor-β1 as a regulator of the serpins/t-PA axis in cerebral ischemia, FASEB J., 13, pp. 1315-1324, (1999)
[8] Feuerstein G.Z., Wang X., Baronne E.C., The role of cytokines in the neuropathology of stroke and neurotrauma, Neuroimmunomodulation, 5, pp. 143-159, (1998)
[9] Fiumelli H., Jabaudon D., Magistretti P.J., Martin J.L., BDNF stimulates expression, activity and release of tissue-type plasminogen activator in mouse cortical neurons Eur, J. Neurosci., 11, pp. 1639-1646, (1999)
[10] Flanders K.C., Lippa C.F., Smith T.W., Pollen D.A., Sporn M.B., Altered expression of transforming growth factor-β in Alzheimer's disease, Neurology, 45, pp. 1561-1569, (1995)

← 1 2 3 4 5 6 →